Feedback

Browsing by H


Use an asterisk (*) for partial word searches (e.g. pemph*)

268 results found.

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Ordering Recommendation:   Not the test of choice for initial evaluation of vitamin D insufficiency. Total vitamin D, 25-hydroxy (0080379) is preferred for diagnosis.
12.
13.
14.
15.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
16.
17.
Ordering Recommendation:   Use to diagnose Hanta pulmonary syndrome (HPS) or hemorrhagic fever with renal syndrome (HFRS).
18.
19.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
20.
21.
Ordering Recommendation:   Diagnostic testing for nonsyndromic hearing loss.
22.
Ordering Recommendation:   Diagnostic testing for GJB6-related nonsyndromic hearing loss. Carrier screening for GJB6-related nonsyndromic hearing loss.
23.
Ordering Recommendation:   For individuals with nonsyndromic hearing loss and no identified mutations in GJB2 or GJB6.
24.
Ordering Recommendation:   Not recommended for evaluation of general hearing loss.
25.
26.
27.
28.
29.
30.
31.
Ordering Recommendation:   Do not use to diagnose H. pylori; order H. pylori urea breath test (Adults 2010476, Children 2010925) or fecal antigen by EIA (0065147).
32.
Ordering Recommendation:   Do not use to diagnose H. pylori; order H. pylori urea breath test (Adults 2010476, Children 2010925) or fecal antigen by EIA (0065147).
33.
Ordering Recommendation:   Do not use to diagnose H. pylori; order H. pylori urea breath test (Adults 2010476, Children 2010925) or fecal antigen by EIA (0065147). Use IgG only if breath and/or stool tests cannot be performed.
34.
Ordering Recommendation:   Do not use to diagnose H. pylori; order H. pylori urea breath test (Adults 2010476, Children 2010925) or fecal antigen by EIA (0065147).
35.
Ordering Recommendation:   As an alternative to the H. pylori urea breath test, order this test to diagnose H. pylori.
36.
Ordering Recommendation:   Use to diagnose H. pylori infection in adults (> 17 years of age). For children and adolescents, refer to Helicobacter pylori Breath test, Pediatric (2010925).
37.
Ordering Recommendation:   Use to diagnose H. pylori infection in children and adolescents (3 to 17 years of age). For adults, refer to Helicobacter pylori Breath Test, Adult (2010476).
38.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
39.
Ordering Recommendation:   Consider for diagnosis of H. pylori infection in children or for susceptibility testing in patients with treatment failure.
40.
41.
Ordering Recommendation:   Not recommended for initial hemochromatosis testing. Confirm clinical diagnosis of hereditary hemochromatosis (HH) in an individual with biochemical findings of iron overload. Screen adult family members of individuals with known HH.
42.
43.
Ordering Recommendation:   Quantifies HbA[2] and HbF in whole blood. Aids in the management of sickle cell disease and in the identification of beta thalassemia carriers.
44.
Ordering Recommendation:   Use to diagnose and monitor diabetes mellitus. Monitor prediabetes.
45.
Ordering Recommendation:   Optimal test for the initial and confirmatory diagnosis of any suspected hemoglobinopathy. A faculty hematopathologist personally directs and interprets each stage of testing to completion. A comprehensive report is provided. Do not use for the follow-up of an individual with a known diagnosis.
46.
Ordering Recommendation:   Effective test for screening and follow-up of individuals with known hemoglobinopathies. The optimal test for the initial diagnosis of a suspected hemoglobinopathy is the Hemoglobin Evaluation Reflexive Cascade (2005792).
47.
48.
Ordering Recommendation:   Order to confirm the diagnosis of Hb Lepore following suggestive hemoglobin evaluation.
49.
50.
51.
52.
53.
54.
Ordering Recommendation:   Identify the causal F8 gene intron 22-A or intron 1 mutation in individuals with established severe hemophilia A. The most comprehensive test for individuals with severe hemophilia A is Hemophilia A (F8) 2 Inversions with Reflex to Sequencing and Reflex to Deletion/Duplication (2001614). For mild to moderate hemophilia A, Hemophilia A (F8) Sequencing (2001747) is recommended.
55.
Ordering Recommendation:   Recommended reflex test to detect the causal F8 mutation in established severe hemophilia A. For mild to moderate hemophilia A, Hemophilia A (F8) Sequencing (2001747) is preferred.
56.
Ordering Recommendation:   Prenatal testing for Hemophilia A caused by a familial F8 gene intron 22-A or intron 1 inversion.
57.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred test is Hemophilia A (F8) Sequencing and Deletion/Duplication reflex.
58.
Ordering Recommendation:   Order to sequence the F8 gene to identify the causal mutation in individuals with established mild to moderate hemophilia A. For severe hemophilia A, Hemophilia A (F8) 2 Inversions with Reflex to Sequencing and Reflex to Deletion/Duplication (2001614) is recommended.
59.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
60.
Ordering Recommendation:   Order to sequence the F9 gene to identify the causal mutation in individuals with established hemophilia B or for carrier testing.
61.
Ordering Recommendation:   Most comprehensive test to confirm diagnosis or determine carrier status for F9 gene mutations.
62.
63.
64.
65.
66.
67.
68.
Ordering Recommendation:   Use for initial screening test for HIT. Confirmation with SRA (2005631) may be necessary depending on clinical presentation.
69.
Ordering Recommendation:   This is the gold standard reflex test for confirming diagnosis of HIT. Test reflexes to serotonin reflex assay if ELISA testing is positive.
70.
71.
Ordering Recommendation:   Initial screening for hepatobiliary inflammation. Panel includes albumin; ALP; AST; ALT; bilirubin, direct; protein, total; and bilirubin, total.
72.
Ordering Recommendation:   This panel is not generally recommended. May be helpful when assessing immunity.
73.
Ordering Recommendation:   Order to diagnose acute hepatitis A virus infection. For panel test that includes HAV IgM, HBV core antibody IgM, HBV surface antigen, and HCV antibody, refer to (0020457).
74.
Ordering Recommendation:   This panel is not recommended to diagnose acute hepatitis A virus infection or for assessing immunity. Order hepatitis A virus IgM antibody (0020093) or hepatitis acute panel (0020457) to diagnose acute infection. Order HAV total antibodies (0020591) for assessing immunity.
75.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
76.
77.
78.
Ordering Recommendation:   Determine exposure to HBV infection. May be helpful in determining which patients are at risk for HBV reactivation and would benefit from prophylactic nucleoside analog treatment prior to initiation of immunosuppression therapy.
79.
Ordering Recommendation:   Can be ordered as part of the acute hepatitis panel which includes HAV IgM, HBV core antibody IgM, HBV surface antigen, and HCV antibody to determine if patient has acute HBV infection. Refer to Hepatitis Panel, Acute with Reflex to HBsAg Confirmation (0020457).
80.
81.
Ordering Recommendation:   Indicates stage of infection. Use to monitor patients with chronic hepatitis B infection and known positive Hepatitis B surface antigen.
82.
Ordering Recommendation:   Monitor post-liver-transplant therapy with hepatitis B immunoglobulin in HBV-positive patients and ascertain response to HBV vaccines.
83.
Ordering Recommendation:   Order for confirmation of HBV in pregnant women (prenatal testing).
84.
Ordering Recommendation:   Can be ordered as part of the acute hepatitis panel which includes HAV IgM, HBV core antibody IgM, HBV surface antigen, and HCV antibody. Refer to Hepatitis Panel, Acute with Reflex to HBsAg Confirmation (0020457).
85.
Ordering Recommendation:   Order for HBV screening in pregnant women (prenatal testing).
86.
Ordering Recommendation:   Detect acute or chronic HBV infection.
87.
Ordering Recommendation:   Monitor HBV therapy; order along with HBV DNA, HBV surface antigen, HBV surface antibody and HBe antigen.
88.
Ordering Recommendation:   Monitor HBV therapy; order along with HBV DNA, HBV surface antigen, HBV surface antibody and HBe antibody.
89.
Ordering Recommendation:   Monitor confirmed chronic hepatitis B infection.
90.
Ordering Recommendation:   Preferred reflex test to confirm active hepatitis C virus (HCV) infection following positive HCV screen. Reflex to genotype aids in prognosis and treatment selection. Order only after positive HCV screen.
91.
Ordering Recommendation:   Use to confirm active HCV infection following positive screen when a higher level of subtype resolution is required. Reflexes to high-resolution genotyping by sequencing.
92.
Ordering Recommendation:   ()Reflex genotyping panel to use for prognosis and treatment selection when a higher level of subtype resolution is required (ie, 1a vs.1b; 1a or 1b vs. Type 6).()Do not order prior to molecular confirmation of positive HCV screen.
93.
Ordering Recommendation:   Recommended testing for HCV genotype 1 patients prior to initiating simeprevir therapy.
94.
Ordering Recommendation:   Preferred single screening test for:()One time screening of population born between 1945-1965()Individuals at risk for HCVPositive results require confirmation by molecular testing (eg, Hepatitis C Virus by Quantitative PCR (0098268) or Hepatitis C Virus (HCV) by Quantitative PCR with Reflex to HCV Genotype by Sequencing (2002685)).
95.
Ordering Recommendation:   Preferred reflex test for screening and confirming HCV in at-risk individuals. If positive, reflexes to quantitative HCV PCR to confirm HCV infection.
96.
Ordering Recommendation:   Preferred single confirmation test for HCV positive screen. Order only after positive HCV screen. Use to monitor chronic disease.
97.
Ordering Recommendation:   ()Preferred genotyping test to use for prognosis and treatment selection. Do not order prior to molecular confirmation of positive hepatitis C virus (HCV) screen.()Assay does not differentiate between Type 1a and Type 1b.
98.
Ordering Recommendation:   Do not order prior to molecular confirmation of positive hepatitis C virus (HCV) screen. Order before initiating HCV therapy to aid in prognosis and therapy selection when a higher level of subtype resolution is required (ie, non 6a/b vs. type 1 and type 1a vs. 1b).
99.
Ordering Recommendation:   Diagnose HDV infection in patient with documented acute or chronic HBV and at risk for HDV infection. Consider ordering HBV core IgM antibody to determine whether HDV infection is a coinfection or a superinfection with HBV.
100.
Ordering Recommendation:   Determine whether HDV infection is acute rather than chronic. Consider ordering HBV IgM core antibody to determine whether HDV infection is a coinfection or a superinfection with HBV.
101.
Ordering Recommendation:   Diagnose HDV infection in patient with documented acute or chronic HBV and risk for HDV infection. Consider ordering HBV IgM ore antibody testing to determine whether HDV infection is a coinfection or a superinfection with HBV.
102.
Ordering Recommendation:   Standalone antibody testing is recommended. Refer to IgM hepatitis E antibody testing for acute disease (2010156) or IgG hepatitis E antibody testing for exposure evaluation (2010151).
103.
Ordering Recommendation:   Use in patients at risk for hepatitis E. Order concurrently with IgM Hepatitis E test.
104.
Ordering Recommendation:   Use in patients at risk for hepatitis E.
105.
106.
Ordering Recommendation:   Order to evaluate viral etiology in patients with acute hepatitis. Not recommended for screening asymptomatic patients. Panel includes HAV IgM, HBV core antibody IgM, HBV surface antigen, HCV antibody.
107.
Ordering Recommendation:   Acceptable panel for surveillance and monitoring of hepatocellular carcinoma.
108.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
109.
110.
Ordering Recommendation:   Confirms etiology of hemolytic anemia in individuals with hemolysis or a family history of hemolytic anemia.
111.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
112.
Ordering Recommendation:   Alternate test when clinical/family history is classic for HHT, but this test does not detect large duplications/deletions.
113.
Ordering Recommendation:   Acceptable test when clinical/family history is classic for HHT.
114.
Ordering Recommendation:   Appropriate test when clinical/family history is classic for HHT.
115.
Ordering Recommendation:   Most comprehensive test to determine the cause of a telangiectasia/AVM disorder.
116.
Ordering Recommendation:   Appropriate test to confirm a clinical diagnosis of a HHT. Consider in particular when a telangiectasia/AVM syndrome is suspected, but symptoms are not classic for HHT.
117.
Ordering Recommendation:   Confirm a suspected diagnosis of hereditary paraganglioma-pheochromocytoma when SDHB, SDHC, and SDHD gene testing is negative.
118.
119.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
120.
121.
122.
123.
Ordering Recommendation:   Aids in determining the cause of elevated HbF. Test confirms suspected deletional hereditary persistence of fetal hemoglobin (HPFH).
124.
125.
126.
Ordering Recommendation:   ()Assess and monitor patient with possible pemphigoid gestationis (herpes gestationis).()Pemphigoid gestationis is a rare disease of pregnancy; consider other types of immunobullous disease testing, (i.e., IgA epithelial BMZ (0092057), IgG collagen type VII (2010905), and/or pemphigus antibody panel (0090650)).
127.
128.
129.
130.
Ordering Recommendation:   Preferred test for detecting herpes simplex virus (HSV) infection in CSF, neonates, or when rapid diagnostic test for suspected HSV infection is necessary.
131.
Ordering Recommendation:   Aids in detection of herpes simplex virus infection. Molecular testing is generally preferred.
132.
Ordering Recommendation:   Aids in detection of herpes simplex virus (HSV) infection. Positive culture reflexes to HSV typing. Molecular testing is generally preferred.
133.
Ordering Recommendation:   Alternate test for detection of herpes simplex virus infection. Negative DFA result reflexes to HSV culture for confirmation. Molecular testing is generally preferred.
134.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
146.
Ordering Recommendation:   Not a first line test for Herpes Simplex Virus (HSV) 2 typing.
147.
148.
149.
150.
151.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
152.
Ordering Recommendation:   Detect HHV6 IgM and IgG antibodies.
153.
Ordering Recommendation:   Not a preferred test for HHV6 antibody testing for acute infection. Refer to HHV-6 IgG and IgM antibody panel (2011721).
154.
Ordering Recommendation:   For HHV6 antibody testing, the panel test is generally preferred. Refer to HHV-6 IgG and IgM antibody panel (2011721).
155.
156.
Ordering Recommendation:   Tissue is the preferred specimen for diagnosing HHV8-related disease. Refer to Herpes Virus 8 by IHC (2003932).
157.
Ordering Recommendation:   May be used as an initial serologic test to detect acute Epstein-Barr virus infectious mononucleosis.
158.
Ordering Recommendation:   Preferred initial serologic test to detect acute Epstein-Barr virus infectious mononucleosis.
159.
Ordering Recommendation:   Preferred test is a reflex panel [Lupus Anticoagulant Reflexive Panel (0030181)].
160.
Ordering Recommendation:   Preferred test to diagnose or identify carriers of Tay Sachs disease, especially in individuals who are pregnant, use oral contraceptives, have severe liver or autoimmune disease, or had previously inconclusive Hexosaminidase A testing in plasma/serum.
161.
Ordering Recommendation:   Use to diagnose or identify carriers of Tay Sachs disease. Individuals who are pregnant, use oral contraceptives, or have severe liver or autoimmune disease should not be tested using plasma or serum. Refer to Hexosaminidase A Percent and Total Hexosamindase in Leukocytes (2008125) for these individuals.
162.
Ordering Recommendation:   Use to diagnose or identify carriers of Tay Sachs disease. Also use to detect carriers of Sandhoff disease. Individuals who are pregnant, use oral contraceptives, or have severe liver or autoimmune disease should not be tested using plasma or serum. Refer to Hexosaminidase A Percent and Total Hexosamindase in Leukocytes (2008125) for these individuals.
163.
Ordering Recommendation:   Evaluate the cause of an isolated prolonged PTT in a patient who is not currently bleeding.
164.
Ordering Recommendation:   Acceptable initial test when antiphospholipid syndrome (APS) is strongly suspected. More specific than cardiolipin IgG and IgM antibodies in the diagnosis of APS.
165.
Ordering Recommendation:   Aids in the detection and subclassification of hyperandrogenism. Most useful in women and children with moderate/severe hirsutism or hirsutism of any degree when it is sudden in onset or rapidly progressive.
166.
Ordering Recommendation:   Aid in evaluation of patient with allergic signs and symptoms, such as anaphylaxis; may assist in diagnosing and monitoring of mast-cell activation disorders.
167.
Ordering Recommendation:   Aid in evaluation of patient with allergic signs and symptoms, such as anaphylaxis; may assist in diagnosing and monitoring of mast-cell activation.
168.
Ordering Recommendation:   Aid in evaluation of patient with allergic signs and symptoms, such as anaphylaxis; may assist in diagnosing and monitoring of mast-cell activation disorders.
169.
170.
171.
172.
173.
174.
175.
176.
177.
Ordering Recommendation:   HIV-1 combined pheno- and genotyping provides antiretroviral susceptibility information for()Protease inhibitors (PI)()Reverse transcriptase inhibitors (NRTI, NNRTI)Useful in clarifying and confirming results from HIV genotyping tests. Intended for patients with viral load >500 copies/mL.
178.
Ordering Recommendation:   HIV-1 sequencing test identifies tropism (CCR5 or CXCR4) of HIV-1 virus in patients being considered for CCR5 or CSCR4 antagonist therapy. If patients viral load is <1,000 HIV-1 copies/mL, refer to tropism assay (2004747).
179.
Ordering Recommendation:   HIV-1 sequencing test provides antiretroviral susceptibility information for()Protease inhibitors (PI)()Reverse transcriptase inhibitors (NRTI, NNRTI)()Integrase inhibitors (INI)()Receptor inhibitors (CCR5 or CXCR4 tropism)HOWEVER, for many patients more targeted testing is sufficient; refer to one of the following tests()HIV-1 Integrase Inhibitor Resistance by Sequencing (2004457)()Human Immunodeficiency Virus 1, Genotype by Sequencing (0055670)()HIV 1 Genotype and Integrase Resistance by Sequencing (2009256)Intended for patients with viral load > 1000 copies/mL.
180.
Ordering Recommendation:   HIV genotyping provides susceptibility information for()Integrase inhibitors (INI)Intended for patients with viral load > 500 copies/mL.
181.
Ordering Recommendation:   HIV-1 genotyping provides antiretroviral susceptibility information for()Protease inhibitors (PI)()Reverse transcriptase inhibitors (NRTI, NNRTI)()Integrase inhibitors (INI)Intended for patients with viral load >1000 copies/mL.
182.
183.
Ordering Recommendation:   Test is intended for pre-transplant allele matching. Do not use for specific disease screening or diagnosis (eg , celiac disease, rheumatologic diseases).
184.
Ordering Recommendation:   Identify HLA-DRB1 and DQB1 allelic polymorphisms for pretransplant allele matching (transplant candidates and their donors).
185.
186.
187.
188.
189.
190.
Ordering Recommendation:   Identify patients prior to treatment with carbamazepine (CBZ) who may be at risk for developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
191.
Ordering Recommendation:   Standard of care prior to abacavir therapy per FDA. Screening test to determine susceptibility to abacavir hypersensitivity syndrome.
192.
Ordering Recommendation:   May assist in the diagnosis of ankylosing spondylitis, juvenile rheumatoid arthritis, and Reiter's syndrome. This test is not diagnostic for these disorders and should be correlated with other clinical signs and symptoms. Flow cytometry is the preferred test for most patients since its sensitivity and specificity are nearly equivalent to the HLA-B27 PCR genotyping test (0050392).
193.
194.
195.
Ordering Recommendation:   Do not use for HLA-related disease screening or diagnosis (eg, celiac disease, narcolepsy, rheumatologic diseases). To rule out celiac disease (when other testing is inconclusive), refer to Celiac Disease (HLA-DQ2 and HLA-DQ8) Genotyping (2005018). When narcolepsy is suspected in symptomatic individuals, refer to Narcolepsy (HLA-DQB1*06:02) Genotyping (2005023).
196.
Ordering Recommendation:   Do not use for specific disease screening or diagnosis (eg , celiac disease, rheumatologic diseases).
197.
198.
Ordering Recommendation:   Detect germline MLH1 mutations. Use in MMR-deficient carcinoma with suggestive IHC (loss of MLH1 and PMS2 protein), absence of BRAF codon 600 mutation, and normal MLH1 methylation studies.
199.
Ordering Recommendation:   Detect germline MSH2 mutations. Use in MMR-deficient carcinoma with suggestive IHC (loss of MSH2 and MSH6 protein) . Detects large MSH2 deletions and EPCAM 3 prime deletions.
200.
Ordering Recommendation:   Detect germline MSH6 mutations. Use in MMR-deficient carcinoma with suggestive IHC (isolated loss of MSH6 protein).
201.
Ordering Recommendation:   Detect germline PMS2 mutations. Use in MMR-deficient carcinoma with suggestive IHC (isolated loss of PMS2 protein).
202.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering.
203.
Ordering Recommendation:   Preferred test for individual with clinical phenotype of HPE and a normal karyotype.
204.
Ordering Recommendation:   Preferred test for fetuses with HPE that is not caused by a structural or numerical chromosome abnormality.
205.
Ordering Recommendation:   Acceptable test for individual with clinical phenotype of HPE and a normal karyotype. Preferred test is Holoprosencephaly Panel, Nonsyndromic, Sequencing and Deletion/Duplication, 11 Genes (2008848).
206.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
207.
Ordering Recommendation:   Not recommended for risk assessment of cardiovascular disease or venous thromboembolism. Acceptable screening test for disorders of methionine metabolism.
208.
209.
Ordering Recommendation:   Initial test for the diagnosis and monitoring of individuals with neuroblastoma. Should be ordered concurrently with Vanillylmandelic Acid (VMA), Urine (0080421).
210.
211.
212.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
213.
Ordering Recommendation:   Not a stand-alone tumor marker for ovarian cancer screening or diagnosis. May be used with CA-125 to monitor epithelial ovarian cancer post therapy if pretreatment levels were elevated. Do not use in mucinous or germ-cell ovarian cancer.
214.
Ordering Recommendation:   Detect and quantify HHV6 subtypes A and B.
215.
216.
217.
Ordering Recommendation:   HIV-1 phenotyping provides antiretroviral susceptibility information for()Protease inhibitors (PI)()Reverse transcriptase inhibitors (NRTI, NNRTI)Intended for patients with viral load >500 copies/mL.
218.
219.
220.
221.
222.
Ordering Recommendation:   HIV-1 genotyping provides antiretroviral susceptibility information for()Protease inhibitors (PI)()Reverse transcriptase inhibitors (NRTI, NNRTI)Intended for patients with viral load >1,000 copies/mL.
223.
224.
Ordering Recommendation:   Order this assay only when a specimen is repeatedly reactive for HIV-1 or HIV 1-2 antibodies.
225.
Ordering Recommendation:   Order only if patient is positive (repeatedly reactive) for combined HIV-1 and HIV-2 antibody screen.
226.
Ordering Recommendation:   HIV genotyping to detect resistance in HIV-1 to antiretroviral drugs. Preferred test is HIV1 Genotype and Integrase Inhibitor Resistance by Sequencing (2009256).
227.
Ordering Recommendation:   HIV-1 combined pheno- and genotyping test provides antiretroviral susceptibility information for()Protease inhibitors (PI)()Reverse transcriptase inhibitors (NRTI, NNRTI)()Integrase inhibitors (INI)Preferred test for patients with known or suspected complex drug resistance patterns (eg, suboptimal virologic response to treatment and viral load rebound).
228.
229.
230.
Ordering Recommendation:   Useful as a supplemental assay for repeatedly reactive third- or fourth-generation HIV screen tests, when following the CDC Proposed HIV Diagnostic Algorithm. This test cannot be used as a rapid screen nor as a follow-up for a positive rapid screen.
231.
Ordering Recommendation:   Order to detect human metapneumovirus (hMPV) in children and immunocompromised adults if suspicion remains in spite of negative hMPV DFA test.
232.
Ordering Recommendation:   Preferred initial test to detect human metapneumovirus (hMPV) in children and adults.
233.
Ordering Recommendation:   Use of FDA-cleared sample preservative (ie, ThinPrep) is recommended. Refer to corresponding ThinPrep testing (2011940).
234.
Ordering Recommendation:   FDA-approved test for triaging women >=30 years with negative cervical cytology (NILM Pap smear) and positive HPV test.
235.
Ordering Recommendation:   Preferred test is HPV high-risk in situ hybridization if determining potential cancer risk.
236.
Ordering Recommendation:   ()FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women >=30 years.()Follow-up test for abnormal cytology results in women >=21 years.
237.
Ordering Recommendation:   Use of FDA-cleared sample preservative (ie, ThinPrep) is recommended. Refer to corresponding ThinPrep testing (2007893 or 2011947).
238.
Ordering Recommendation:   ()FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women >=30 years.()Follow-up test for abnormal cytology results in women >=21 years.Other ThinPrep testing options include hrHPV by TMA (2007893), hrHPV by PCR (2011947), and hrHPV 16 & 18 by TMA (2011940).
239.
Ordering Recommendation:   Preferred in situ hybridization test to detect high-risk HPV subtypes in formalin-fixed, paraffin-embedded tissue.
240.
Ordering Recommendation:   Use of FDA-cleared sample preservative (ie, ThinPrep) is recommended. Refer to corresponding ThinPrep testing (2007893 or 2011947).
241.
Ordering Recommendation:   ()FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) for women >=30 years.()Follow-up test for abnormal cytology results in women >=21 years.
242.
Ordering Recommendation:   FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women >=30 years; genotyping performed for triaging women to colposcopy who are cytology-negative (NILM) and HPV-positive.
243.
Ordering Recommendation:   ()FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women >=30 years.()Follow-up test for abnormal cytology results in women >=21 years.
244.
Ordering Recommendation:   Use of FDA-cleared sample preservative (ie, ThinPrep) is recommended. Refer to corresponding ThinPrep test (2011940).
245.
Ordering Recommendation:   ()FDA-approved platform for primary HPV screening in women >=25 years.()FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women >=30 years.
246.
247.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
248.
249.
Ordering Recommendation:   Confirm antibody test results for a positive screening test (HTLV types I and II).
250.
251.
252.
253.
254.
Ordering Recommendation:   Diagnostic testing for Huntington disease. Predictive testing for Huntington disease.
255.
Ordering Recommendation:   Noninvasive assessment of liver status.
256.
257.
258.
259.
260.
Ordering Recommendation:   Confirm suspected hyper-IgM syndrome in individual with clinical symptoms.
261.
262.
263.
264.
Ordering Recommendation:   Diagnostic testing for hypochondroplasia.
265.
Ordering Recommendation:   Preferred test for evaluating if etiology of hypoglycemia is sulfonylurea ingestion.
266.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
267.
Ordering Recommendation:   Recommended test for confirming a diagnosis of hypohydrotic ectodermal dysplasia.
268.
Ordering Recommendation:   Detects the majority of causative hypohydrotic ectodermal dysplasia mutations, but will not detect rare large deletions or duplications.